Annals of Oncology Advance Access originally published online on August 5, 2005
Annals of Oncology 2005 16(11):1806-1810; doi:10.1093/annonc/mdi358
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Endocrine pancreatic tumors: factors correlated with survival
1 Dipartimento di Medicina Interna e Gastroenterologia, 2 Dipartimento Clinico di Scienze Chirurgiche ed Anestesiologiche and 3 Dipartimento Clinico di Scienze Radiologiche ed Istopatologiche, Università di Bologna, Italy
* Correspondence to: Prof P. Tomassetti, Department of Internal Medicine and Gastroenterology, University of Bologna, Policlinico S.Orsola-Malpighi, Via Massarenti, 9, 40138 Bologna, Italy. Tel/Fax: +39-051-6364186; E-mail: paola.tomassetti{at}unibo.it
Background: The aim of this study was to evaluate the survival rate of patients with endocrine tumors of the pancreas, functioning or non-functioning, associated or not with MEN 1 syndrome.
Patients and methods: Eighty-three patients with pancreatic endocrine tumors diagnosed in our department from 1978 to 2003 were studied.
Results: The study included 37 men (44.6%) and 46 women (55.4%). The median age of patients at diagnosis was 55 years (range 19–81 years). Fifty-two patients (62.7%) had non-functioning endocrine tumors, 16 (19.3%) had functioning endocrine tumors and 15 (18.1%) had MEN 1 disease with pancreatic involvement. Twenty-seven patients (32.5%) had liver metastases at the time of diagnosis, involvement of the lymph nodes was found in 47 out of 79 patients (59.5%). Forty patients (48.2%) had radical surgery, 20 (24.1%) had palliative surgery and 53 were treated medically. The survival rate was significantly related to the presence of metastases, lymph node involvement, and the type of tumor and treatment.
Conclusions: Tumor resection, the absence of liver and lymph node metastases, and the presence of MEN 1 syndrome are related to a better survival rate. Radical surgery continues to have a central role in the therapeutic approach to endocrine tumors of the pancreas.
Key words: endocrine pancreatic tumor, gastrinoma, multiple endocrine neoplasia, octreotide, surgical procedure
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Durante, H. Boukheris, C. Dromain, P. Duvillard, S. Leboulleux, D. Elias, T. de Baere, D. Malka, J. Lumbroso, J. Guigay, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma Endocr. Relat. Cancer, June 1, 2009; 16(2): 585 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G Thrumurthy, R. S Date, M. M Mughal, K. G Pursnani, and J. B Ward The surgical management of pancreaticoduodenal tumours in multiple endocrine neoplasia type 1 BMJ Case Reports, April 14, 2009; 2009(apr07_2): bcr0820080763 - bcr0820080763. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Malago, M. D'Onofrio, G. A. Zamboni, N. Faccioli, M. Falconi, L. Boninsegna, and R. P. Mucelli Contrast-Enhanced Sonography of Nonfunctioning Pancreatic Neuroendocrine Tumors Am. J. Roentgenol., February 1, 2009; 192(2): 424 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ekeblad, B. Skogseid, K. Dunder, K. Oberg, and B. Eriksson Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution Clin. Cancer Res., December 1, 2008; 14(23): 7798 - 7803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Couvelard, L. Deschamps, V. Rebours, A. Sauvanet, K. Gatter, F. Pezzella, P. Ruszniewski, and P. Bedossa Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors Clin. Cancer Res., October 15, 2008; 14(20): 6634 - 6639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bettini, L. Boninsegna, W. Mantovani, P. Capelli, C. Bassi, P. Pederzoli, G. F. Delle Fave, F. Panzuto, A. Scarpa, and M. Falconi Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours Ann. Onc., May 1, 2008; 19(5): 903 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Liapi, J.-F. Geschwind, J. A. Vossen, M. Buijs, C. S. Georgiades, D. A. Bluemke, and I. R. Kamel Functional MRI Evaluation of Tumor Response in Patients with Neuroendocrine Hepatic Metastasis Treated with Transcatheter Arterial Chemoembolization Am. J. Roentgenol., January 1, 2008; 190(1): 67 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y M H Jonkers, S M H Claessen, A Perren, A M Schmitt, L J Hofland, W de Herder, R R de Krijger, A A J Verhofstad, A R Hermus, J A Kummer, et al. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients Endocr. Relat. Cancer, September 1, 2007; 14(3): 769 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Zatelli, M. Torta, A. Leon, M. R. Ambrosio, M. Gion, P. Tomassetti, F. De Braud, G. Delle Fave, L. Dogliotti, E. C d. Uberti, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study Endocr. Relat. Cancer, June 1, 2007; 14(2): 473 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Campana, F. Nori, L. Piscitelli, A. M. Morselli-Labate, R. Pezzilli, R. Corinaldesi, and P. Tomassetti Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors? J. Clin. Oncol., May 20, 2007; 25(15): 1967 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Florio, G. Capurso, M. Milione, F. Panzuto, R. Geremia, G. D. Fave, and C. Sette Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells Endocr. Relat. Cancer, March 1, 2007; 14(1): 111 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer, June 1, 2006; 13(2): 541 - 558. [Abstract] [Full Text] [PDF]
|
|